Global Microbiome Therapeutics Market Analysis and Forecast 2024-2030
Summary
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
According to APO Research, The global Microbiome Therapeutics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Microbiome Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Microbiome Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Microbiome Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Microbiome Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Microbiome Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Microbiome Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Microbiome Therapeutics segment by Company
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Microbiome Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Microbiome Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome Therapeutics revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
The human microbiome is the collection of all the microorganisms living in association with the human body. These communities consist of a variety of microorganisms including eukaryotes, archaea, bacteria and viruses. Bacteria in an average human body number ten times more than human cells, for a total of about 1000 more genes than are present in the human genome. Because of their small size, however, microorganisms make up only about 1 to 3 percent of our body mass (that's 2 to 6 pounds of bacteria in a 200-pound adult).
These microbes are generally not harmful to us; in fact they are essential for maintaining health. For example, they produce some vitamins that we do not have the genes to make, break down our food to extract nutrients we need to survive, teach our immune systems how to recognize dangerous invaders and even produce helpful anti-inflammatory compounds that fight off other disease-causing microbes.
An ever-growing number of studies have demonstrated that changes in the composition of our microbiomes correlate with numerous disease states, raising the possibility that manipulation of these communities could be used to treat disease.
According to APO Research, The global Microbiome Therapeutics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Microbiome Therapeutics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Microbiome Therapeutics include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics, Interxon, PureTech, Synlogic, Enterome BioScience, 4D Pharma and Second Genome, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Microbiome Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Microbiome Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Microbiome Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Microbiome Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Microbiome Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Microbiome Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Microbiome Therapeutics segment by Company
- Seres Therapeutics
- Assembly Biosciences
- Synthetic Biologics
- Interxon
- PureTech
- Synlogic
- Enterome BioScience
- 4D Pharma
- Second Genome
- AOBiome
- C3 Jian
- Rebiotix
- MicroBiome Therapeutics LLC
- Metabiomics
- Ritter Pharmaceuticals
- Symberix
- OpenBiome
- Azitra
- Symbiotix Biotherapies
- Osel
- Metabogen
- Upper GIT
- Lower GIT
- C. difficile Infection (CDI)
- Inflammatory Bowel Disease (IBD)
- Orphan Drug
- Immuno-oncology
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Microbiome Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Microbiome Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Microbiome Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Microbiome Therapeutics revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Microbiome Therapeutics Market by Type
1.2.1 Global Microbiome Therapeutics Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Upper GIT
1.2.3 Lower GIT
1.3 Microbiome Therapeutics Market by Application
1.3.1 Global Microbiome Therapeutics Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 C. difficile Infection (CDI)
1.3.3 Inflammatory Bowel Disease (IBD)
1.3.4 Orphan Drug
1.3.5 Immuno-oncology
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 MICROBIOME THERAPEUTICS MARKET DYNAMICS
2.1 Microbiome Therapeutics Industry Trends
2.2 Microbiome Therapeutics Industry Drivers
2.3 Microbiome Therapeutics Industry Opportunities and Challenges
2.4 Microbiome Therapeutics Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Microbiome Therapeutics Market Perspective (2019-2030)
3.2 Global Microbiome Therapeutics Growth Trends by Region
3.2.1 Global Microbiome Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Microbiome Therapeutics Market Size by Region (2019-2024)
3.2.3 Global Microbiome Therapeutics Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Microbiome Therapeutics Revenue by Players
4.1.1 Global Microbiome Therapeutics Revenue by Players (2019-2024)
4.1.2 Global Microbiome Therapeutics Revenue Market Share by Players (2019-2024)
4.1.3 Global Microbiome Therapeutics Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Microbiome Therapeutics Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Microbiome Therapeutics Key Players Headquarters & Area Served
4.4 Global Microbiome Therapeutics Players, Product Type & Application
4.5 Global Microbiome Therapeutics Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Microbiome Therapeutics Market CR5 and HHI
4.6.2 Global Top 5 and 10 Microbiome Therapeutics Players Market Share by Revenue in 2023
4.6.3 2023 Microbiome Therapeutics Tier 1, Tier 2, and Tier
5 MICROBIOME THERAPEUTICS MARKET SIZE BY TYPE
5.1 Global Microbiome Therapeutics Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Microbiome Therapeutics Revenue by Type (2019-2030)
5.3 Global Microbiome Therapeutics Revenue Market Share by Type (2019-2030)
6 MICROBIOME THERAPEUTICS MARKET SIZE BY APPLICATION
6.1 Global Microbiome Therapeutics Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Microbiome Therapeutics Revenue by Application (2019-2030)
6.3 Global Microbiome Therapeutics Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Seres Therapeutics
7.1.1 Seres Therapeutics Comapny Information
7.1.2 Seres Therapeutics Business Overview
7.1.3 Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
7.1.5 Seres Therapeutics Recent Developments
7.2 Assembly Biosciences
7.2.1 Assembly Biosciences Comapny Information
7.2.2 Assembly Biosciences Business Overview
7.2.3 Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
7.2.5 Assembly Biosciences Recent Developments
7.3 Synthetic Biologics
7.3.1 Synthetic Biologics Comapny Information
7.3.2 Synthetic Biologics Business Overview
7.3.3 Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
7.3.5 Synthetic Biologics Recent Developments
7.4 Interxon
7.4.1 Interxon Comapny Information
7.4.2 Interxon Business Overview
7.4.3 Interxon Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.4.4 Interxon Microbiome Therapeutics Product Portfolio
7.4.5 Interxon Recent Developments
7.5 PureTech
7.5.1 PureTech Comapny Information
7.5.2 PureTech Business Overview
7.5.3 PureTech Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.5.4 PureTech Microbiome Therapeutics Product Portfolio
7.5.5 PureTech Recent Developments
7.6 Synlogic
7.6.1 Synlogic Comapny Information
7.6.2 Synlogic Business Overview
7.6.3 Synlogic Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.6.4 Synlogic Microbiome Therapeutics Product Portfolio
7.6.5 Synlogic Recent Developments
7.7 Enterome BioScience
7.7.1 Enterome BioScience Comapny Information
7.7.2 Enterome BioScience Business Overview
7.7.3 Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
7.7.5 Enterome BioScience Recent Developments
7.8 4D Pharma
7.8.1 4D Pharma Comapny Information
7.8.2 4D Pharma Business Overview
7.8.3 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
7.8.5 4D Pharma Recent Developments
7.9 Second Genome
7.9.1 Second Genome Comapny Information
7.9.2 Second Genome Business Overview
7.9.3 Second Genome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.9.4 Second Genome Microbiome Therapeutics Product Portfolio
7.9.5 Second Genome Recent Developments
7.10 AOBiome
7.10.1 AOBiome Comapny Information
7.10.2 AOBiome Business Overview
7.10.3 AOBiome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.10.4 AOBiome Microbiome Therapeutics Product Portfolio
7.10.5 AOBiome Recent Developments
7.11 C3 Jian
7.11.1 C3 Jian Comapny Information
7.11.2 C3 Jian Business Overview
7.11.3 C3 Jian Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
7.11.5 C3 Jian Recent Developments
7.12 Rebiotix
7.12.1 Rebiotix Comapny Information
7.12.2 Rebiotix Business Overview
7.12.3 Rebiotix Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
7.12.5 Rebiotix Recent Developments
7.13 MicroBiome Therapeutics LLC
7.13.1 MicroBiome Therapeutics LLC Comapny Information
7.13.2 MicroBiome Therapeutics LLC Business Overview
7.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
7.13.5 MicroBiome Therapeutics LLC Recent Developments
7.14 Metabiomics
7.14.1 Metabiomics Comapny Information
7.14.2 Metabiomics Business Overview
7.14.3 Metabiomics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
7.14.5 Metabiomics Recent Developments
7.15 Ritter Pharmaceuticals
7.15.1 Ritter Pharmaceuticals Comapny Information
7.15.2 Ritter Pharmaceuticals Business Overview
7.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
7.15.5 Ritter Pharmaceuticals Recent Developments
7.16 Symberix
7.16.1 Symberix Comapny Information
7.16.2 Symberix Business Overview
7.16.3 Symberix Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.16.4 Symberix Microbiome Therapeutics Product Portfolio
7.16.5 Symberix Recent Developments
7.17 OpenBiome
7.17.1 OpenBiome Comapny Information
7.17.2 OpenBiome Business Overview
7.17.3 OpenBiome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
7.17.5 OpenBiome Recent Developments
7.18 Azitra
7.18.1 Azitra Comapny Information
7.18.2 Azitra Business Overview
7.18.3 Azitra Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.18.4 Azitra Microbiome Therapeutics Product Portfolio
7.18.5 Azitra Recent Developments
7.19 Symbiotix Biotherapies
7.19.1 Symbiotix Biotherapies Comapny Information
7.19.2 Symbiotix Biotherapies Business Overview
7.19.3 Symbiotix Biotherapies Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
7.19.5 Symbiotix Biotherapies Recent Developments
7.20 Osel
7.20.1 Osel Comapny Information
7.20.2 Osel Business Overview
7.20.3 Osel Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.20.4 Osel Microbiome Therapeutics Product Portfolio
7.20.5 Osel Recent Developments
7.21 Metabogen
7.21.1 Metabogen Comapny Information
7.21.2 Metabogen Business Overview
7.21.3 Metabogen Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.21.4 Metabogen Microbiome Therapeutics Product Portfolio
7.21.5 Metabogen Recent Developments
8 NORTH AMERICA
8.1 North America Microbiome Therapeutics Revenue (2019-2030)
8.2 North America Microbiome Therapeutics Revenue by Type (2019-2030)
8.2.1 North America Microbiome Therapeutics Revenue by Type (2019-2024)
8.2.2 North America Microbiome Therapeutics Revenue by Type (2025-2030)
8.3 North America Microbiome Therapeutics Revenue Share by Type (2019-2030)
8.4 North America Microbiome Therapeutics Revenue by Application (2019-2030)
8.4.1 North America Microbiome Therapeutics Revenue by Application (2019-2024)
8.4.2 North America Microbiome Therapeutics Revenue by Application (2025-2030)
8.5 North America Microbiome Therapeutics Revenue Share by Application (2019-2030)
8.6 North America Microbiome Therapeutics Revenue by Country
8.6.1 North America Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Microbiome Therapeutics Revenue by Country (2019-2024)
8.6.3 North America Microbiome Therapeutics Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Microbiome Therapeutics Revenue (2019-2030)
9.2 Europe Microbiome Therapeutics Revenue by Type (2019-2030)
9.2.1 Europe Microbiome Therapeutics Revenue by Type (2019-2024)
9.2.2 Europe Microbiome Therapeutics Revenue by Type (2025-2030)
9.3 Europe Microbiome Therapeutics Revenue Share by Type (2019-2030)
9.4 Europe Microbiome Therapeutics Revenue by Application (2019-2030)
9.4.1 Europe Microbiome Therapeutics Revenue by Application (2019-2024)
9.4.2 Europe Microbiome Therapeutics Revenue by Application (2025-2030)
9.5 Europe Microbiome Therapeutics Revenue Share by Application (2019-2030)
9.6 Europe Microbiome Therapeutics Revenue by Country
9.6.1 Europe Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Microbiome Therapeutics Revenue by Country (2019-2024)
9.6.3 Europe Microbiome Therapeutics Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Microbiome Therapeutics Revenue (2019-2030)
10.2 China Microbiome Therapeutics Revenue by Type (2019-2030)
10.2.1 China Microbiome Therapeutics Revenue by Type (2019-2024)
10.2.2 China Microbiome Therapeutics Revenue by Type (2025-2030)
10.3 China Microbiome Therapeutics Revenue Share by Type (2019-2030)
10.4 China Microbiome Therapeutics Revenue by Application (2019-2030)
10.4.1 China Microbiome Therapeutics Revenue by Application (2019-2024)
10.4.2 China Microbiome Therapeutics Revenue by Application (2025-2030)
10.5 China Microbiome Therapeutics Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Microbiome Therapeutics Revenue (2019-2030)
11.2 Asia Microbiome Therapeutics Revenue by Type (2019-2030)
11.2.1 Asia Microbiome Therapeutics Revenue by Type (2019-2024)
11.2.2 Asia Microbiome Therapeutics Revenue by Type (2025-2030)
11.3 Asia Microbiome Therapeutics Revenue Share by Type (2019-2030)
11.4 Asia Microbiome Therapeutics Revenue by Application (2019-2030)
11.4.1 Asia Microbiome Therapeutics Revenue by Application (2019-2024)
11.4.2 Asia Microbiome Therapeutics Revenue by Application (2025-2030)
11.5 Asia Microbiome Therapeutics Revenue Share by Application (2019-2030)
11.6 Asia Microbiome Therapeutics Revenue by Country
11.6.1 Asia Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Microbiome Therapeutics Revenue by Country (2019-2024)
11.6.3 Asia Microbiome Therapeutics Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Microbiome Therapeutics Revenue (2019-2030)
12.2 MEALA Microbiome Therapeutics Revenue by Type (2019-2030)
12.2.1 MEALA Microbiome Therapeutics Revenue by Type (2019-2024)
12.2.2 MEALA Microbiome Therapeutics Revenue by Type (2025-2030)
12.3 MEALA Microbiome Therapeutics Revenue Share by Type (2019-2030)
12.4 MEALA Microbiome Therapeutics Revenue by Application (2019-2030)
12.4.1 MEALA Microbiome Therapeutics Revenue by Application (2019-2024)
12.4.2 MEALA Microbiome Therapeutics Revenue by Application (2025-2030)
12.5 MEALA Microbiome Therapeutics Revenue Share by Application (2019-2030)
12.6 MEALA Microbiome Therapeutics Revenue by Country
12.6.1 MEALA Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Microbiome Therapeutics Revenue by Country (2019-2024)
12.6.3 MEALA Microbiome Therapeutics Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
1.1 Product Definition
1.2 Microbiome Therapeutics Market by Type
1.2.1 Global Microbiome Therapeutics Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Upper GIT
1.2.3 Lower GIT
1.3 Microbiome Therapeutics Market by Application
1.3.1 Global Microbiome Therapeutics Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 C. difficile Infection (CDI)
1.3.3 Inflammatory Bowel Disease (IBD)
1.3.4 Orphan Drug
1.3.5 Immuno-oncology
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 MICROBIOME THERAPEUTICS MARKET DYNAMICS
2.1 Microbiome Therapeutics Industry Trends
2.2 Microbiome Therapeutics Industry Drivers
2.3 Microbiome Therapeutics Industry Opportunities and Challenges
2.4 Microbiome Therapeutics Industry Restraints
3 GLOBAL GROWTH PERSPECTIVE
3.1 Global Microbiome Therapeutics Market Perspective (2019-2030)
3.2 Global Microbiome Therapeutics Growth Trends by Region
3.2.1 Global Microbiome Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Microbiome Therapeutics Market Size by Region (2019-2024)
3.2.3 Global Microbiome Therapeutics Market Size by Region (2025-2030)
4 COMPETITIVE LANDSCAPE BY PLAYERS
4.1 Global Microbiome Therapeutics Revenue by Players
4.1.1 Global Microbiome Therapeutics Revenue by Players (2019-2024)
4.1.2 Global Microbiome Therapeutics Revenue Market Share by Players (2019-2024)
4.1.3 Global Microbiome Therapeutics Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Microbiome Therapeutics Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Microbiome Therapeutics Key Players Headquarters & Area Served
4.4 Global Microbiome Therapeutics Players, Product Type & Application
4.5 Global Microbiome Therapeutics Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Microbiome Therapeutics Market CR5 and HHI
4.6.2 Global Top 5 and 10 Microbiome Therapeutics Players Market Share by Revenue in 2023
4.6.3 2023 Microbiome Therapeutics Tier 1, Tier 2, and Tier
5 MICROBIOME THERAPEUTICS MARKET SIZE BY TYPE
5.1 Global Microbiome Therapeutics Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Microbiome Therapeutics Revenue by Type (2019-2030)
5.3 Global Microbiome Therapeutics Revenue Market Share by Type (2019-2030)
6 MICROBIOME THERAPEUTICS MARKET SIZE BY APPLICATION
6.1 Global Microbiome Therapeutics Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Microbiome Therapeutics Revenue by Application (2019-2030)
6.3 Global Microbiome Therapeutics Revenue Market Share by Application (2019-2030)
7 COMPANY PROFILES
7.1 Seres Therapeutics
7.1.1 Seres Therapeutics Comapny Information
7.1.2 Seres Therapeutics Business Overview
7.1.3 Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.1.4 Seres Therapeutics Microbiome Therapeutics Product Portfolio
7.1.5 Seres Therapeutics Recent Developments
7.2 Assembly Biosciences
7.2.1 Assembly Biosciences Comapny Information
7.2.2 Assembly Biosciences Business Overview
7.2.3 Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.2.4 Assembly Biosciences Microbiome Therapeutics Product Portfolio
7.2.5 Assembly Biosciences Recent Developments
7.3 Synthetic Biologics
7.3.1 Synthetic Biologics Comapny Information
7.3.2 Synthetic Biologics Business Overview
7.3.3 Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.3.4 Synthetic Biologics Microbiome Therapeutics Product Portfolio
7.3.5 Synthetic Biologics Recent Developments
7.4 Interxon
7.4.1 Interxon Comapny Information
7.4.2 Interxon Business Overview
7.4.3 Interxon Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.4.4 Interxon Microbiome Therapeutics Product Portfolio
7.4.5 Interxon Recent Developments
7.5 PureTech
7.5.1 PureTech Comapny Information
7.5.2 PureTech Business Overview
7.5.3 PureTech Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.5.4 PureTech Microbiome Therapeutics Product Portfolio
7.5.5 PureTech Recent Developments
7.6 Synlogic
7.6.1 Synlogic Comapny Information
7.6.2 Synlogic Business Overview
7.6.3 Synlogic Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.6.4 Synlogic Microbiome Therapeutics Product Portfolio
7.6.5 Synlogic Recent Developments
7.7 Enterome BioScience
7.7.1 Enterome BioScience Comapny Information
7.7.2 Enterome BioScience Business Overview
7.7.3 Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.7.4 Enterome BioScience Microbiome Therapeutics Product Portfolio
7.7.5 Enterome BioScience Recent Developments
7.8 4D Pharma
7.8.1 4D Pharma Comapny Information
7.8.2 4D Pharma Business Overview
7.8.3 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.8.4 4D Pharma Microbiome Therapeutics Product Portfolio
7.8.5 4D Pharma Recent Developments
7.9 Second Genome
7.9.1 Second Genome Comapny Information
7.9.2 Second Genome Business Overview
7.9.3 Second Genome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.9.4 Second Genome Microbiome Therapeutics Product Portfolio
7.9.5 Second Genome Recent Developments
7.10 AOBiome
7.10.1 AOBiome Comapny Information
7.10.2 AOBiome Business Overview
7.10.3 AOBiome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.10.4 AOBiome Microbiome Therapeutics Product Portfolio
7.10.5 AOBiome Recent Developments
7.11 C3 Jian
7.11.1 C3 Jian Comapny Information
7.11.2 C3 Jian Business Overview
7.11.3 C3 Jian Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.11.4 C3 Jian Microbiome Therapeutics Product Portfolio
7.11.5 C3 Jian Recent Developments
7.12 Rebiotix
7.12.1 Rebiotix Comapny Information
7.12.2 Rebiotix Business Overview
7.12.3 Rebiotix Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.12.4 Rebiotix Microbiome Therapeutics Product Portfolio
7.12.5 Rebiotix Recent Developments
7.13 MicroBiome Therapeutics LLC
7.13.1 MicroBiome Therapeutics LLC Comapny Information
7.13.2 MicroBiome Therapeutics LLC Business Overview
7.13.3 MicroBiome Therapeutics LLC Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.13.4 MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
7.13.5 MicroBiome Therapeutics LLC Recent Developments
7.14 Metabiomics
7.14.1 Metabiomics Comapny Information
7.14.2 Metabiomics Business Overview
7.14.3 Metabiomics Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.14.4 Metabiomics Microbiome Therapeutics Product Portfolio
7.14.5 Metabiomics Recent Developments
7.15 Ritter Pharmaceuticals
7.15.1 Ritter Pharmaceuticals Comapny Information
7.15.2 Ritter Pharmaceuticals Business Overview
7.15.3 Ritter Pharmaceuticals Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.15.4 Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
7.15.5 Ritter Pharmaceuticals Recent Developments
7.16 Symberix
7.16.1 Symberix Comapny Information
7.16.2 Symberix Business Overview
7.16.3 Symberix Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.16.4 Symberix Microbiome Therapeutics Product Portfolio
7.16.5 Symberix Recent Developments
7.17 OpenBiome
7.17.1 OpenBiome Comapny Information
7.17.2 OpenBiome Business Overview
7.17.3 OpenBiome Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.17.4 OpenBiome Microbiome Therapeutics Product Portfolio
7.17.5 OpenBiome Recent Developments
7.18 Azitra
7.18.1 Azitra Comapny Information
7.18.2 Azitra Business Overview
7.18.3 Azitra Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.18.4 Azitra Microbiome Therapeutics Product Portfolio
7.18.5 Azitra Recent Developments
7.19 Symbiotix Biotherapies
7.19.1 Symbiotix Biotherapies Comapny Information
7.19.2 Symbiotix Biotherapies Business Overview
7.19.3 Symbiotix Biotherapies Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.19.4 Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
7.19.5 Symbiotix Biotherapies Recent Developments
7.20 Osel
7.20.1 Osel Comapny Information
7.20.2 Osel Business Overview
7.20.3 Osel Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.20.4 Osel Microbiome Therapeutics Product Portfolio
7.20.5 Osel Recent Developments
7.21 Metabogen
7.21.1 Metabogen Comapny Information
7.21.2 Metabogen Business Overview
7.21.3 Metabogen Microbiome Therapeutics Revenue and Gross Margin (2019-2024)
7.21.4 Metabogen Microbiome Therapeutics Product Portfolio
7.21.5 Metabogen Recent Developments
8 NORTH AMERICA
8.1 North America Microbiome Therapeutics Revenue (2019-2030)
8.2 North America Microbiome Therapeutics Revenue by Type (2019-2030)
8.2.1 North America Microbiome Therapeutics Revenue by Type (2019-2024)
8.2.2 North America Microbiome Therapeutics Revenue by Type (2025-2030)
8.3 North America Microbiome Therapeutics Revenue Share by Type (2019-2030)
8.4 North America Microbiome Therapeutics Revenue by Application (2019-2030)
8.4.1 North America Microbiome Therapeutics Revenue by Application (2019-2024)
8.4.2 North America Microbiome Therapeutics Revenue by Application (2025-2030)
8.5 North America Microbiome Therapeutics Revenue Share by Application (2019-2030)
8.6 North America Microbiome Therapeutics Revenue by Country
8.6.1 North America Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Microbiome Therapeutics Revenue by Country (2019-2024)
8.6.3 North America Microbiome Therapeutics Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 EUROPE
9.1 Europe Microbiome Therapeutics Revenue (2019-2030)
9.2 Europe Microbiome Therapeutics Revenue by Type (2019-2030)
9.2.1 Europe Microbiome Therapeutics Revenue by Type (2019-2024)
9.2.2 Europe Microbiome Therapeutics Revenue by Type (2025-2030)
9.3 Europe Microbiome Therapeutics Revenue Share by Type (2019-2030)
9.4 Europe Microbiome Therapeutics Revenue by Application (2019-2030)
9.4.1 Europe Microbiome Therapeutics Revenue by Application (2019-2024)
9.4.2 Europe Microbiome Therapeutics Revenue by Application (2025-2030)
9.5 Europe Microbiome Therapeutics Revenue Share by Application (2019-2030)
9.6 Europe Microbiome Therapeutics Revenue by Country
9.6.1 Europe Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Microbiome Therapeutics Revenue by Country (2019-2024)
9.6.3 Europe Microbiome Therapeutics Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 CHINA
10.1 China Microbiome Therapeutics Revenue (2019-2030)
10.2 China Microbiome Therapeutics Revenue by Type (2019-2030)
10.2.1 China Microbiome Therapeutics Revenue by Type (2019-2024)
10.2.2 China Microbiome Therapeutics Revenue by Type (2025-2030)
10.3 China Microbiome Therapeutics Revenue Share by Type (2019-2030)
10.4 China Microbiome Therapeutics Revenue by Application (2019-2030)
10.4.1 China Microbiome Therapeutics Revenue by Application (2019-2024)
10.4.2 China Microbiome Therapeutics Revenue by Application (2025-2030)
10.5 China Microbiome Therapeutics Revenue Share by Application (2019-2030)
11 ASIA (EXCLUDING CHINA)
11.1 Asia Microbiome Therapeutics Revenue (2019-2030)
11.2 Asia Microbiome Therapeutics Revenue by Type (2019-2030)
11.2.1 Asia Microbiome Therapeutics Revenue by Type (2019-2024)
11.2.2 Asia Microbiome Therapeutics Revenue by Type (2025-2030)
11.3 Asia Microbiome Therapeutics Revenue Share by Type (2019-2030)
11.4 Asia Microbiome Therapeutics Revenue by Application (2019-2030)
11.4.1 Asia Microbiome Therapeutics Revenue by Application (2019-2024)
11.4.2 Asia Microbiome Therapeutics Revenue by Application (2025-2030)
11.5 Asia Microbiome Therapeutics Revenue Share by Application (2019-2030)
11.6 Asia Microbiome Therapeutics Revenue by Country
11.6.1 Asia Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Microbiome Therapeutics Revenue by Country (2019-2024)
11.6.3 Asia Microbiome Therapeutics Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 MIDDLE EAST, AFRICA, LATIN AMERICA
12.1 MEALA Microbiome Therapeutics Revenue (2019-2030)
12.2 MEALA Microbiome Therapeutics Revenue by Type (2019-2030)
12.2.1 MEALA Microbiome Therapeutics Revenue by Type (2019-2024)
12.2.2 MEALA Microbiome Therapeutics Revenue by Type (2025-2030)
12.3 MEALA Microbiome Therapeutics Revenue Share by Type (2019-2030)
12.4 MEALA Microbiome Therapeutics Revenue by Application (2019-2030)
12.4.1 MEALA Microbiome Therapeutics Revenue by Application (2019-2024)
12.4.2 MEALA Microbiome Therapeutics Revenue by Application (2025-2030)
12.5 MEALA Microbiome Therapeutics Revenue Share by Application (2019-2030)
12.6 MEALA Microbiome Therapeutics Revenue by Country
12.6.1 MEALA Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Microbiome Therapeutics Revenue by Country (2019-2024)
12.6.3 MEALA Microbiome Therapeutics Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 CONCLUDING INSIGHTS
14 APPENDIX
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
LIST OF TABLES
Table 1. Global Microbiome Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Upper GIT Major Manufacturers
Table 2. Lower GIT Major Manufacturers
Table 3. Global Microbiome Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 4. C. difficile Infection (CDI) Major Manufacturers
Table 5. Inflammatory Bowel Disease (IBD) Major Manufacturers
Table 6. Orphan Drug Major Manufacturers
Table 7. Immuno-oncology Major Manufacturers
Table 8. Others Major Manufacturers
Table 9. Microbiome Therapeutics Industry Trends
Table 10. Microbiome Therapeutics Industry Drivers
Table 11. Microbiome Therapeutics Industry Opportunities and Challenges
Table 12. Microbiome Therapeutics Industry Restraints
Table 13. Global Microbiome Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Microbiome Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Microbiome Therapeutics Market Share by Region (2019-2024)
Table 16. Global Microbiome Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Microbiome Therapeutics Market Share by Region (2025-2030)
Table 18. Global Microbiome Therapeutics Revenue by Players (US$ Million) & (2019-2024)
Table 19. Global Microbiome Therapeutics Revenue Market Share by Players (2019-2024)
Table 20. Global Microbiome Therapeutics Key Players Ranking, 2022 VS 2023 VS 2024
Table 21. Global Microbiome Therapeutics Key Players Headquarters & Area Served
Table 22. Global Microbiome Therapeutics Players, Product Type & Application
Table 23. Global Microbiome Therapeutics Players Commercialization Time
Table 24. Global Players Market Concentration Ratio (CR5 and HHI)
Table 25. Global Microbiome Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 26. Global Microbiome Therapeutics Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 28. Global Microbiome Therapeutics Revenue by Type (2025-2030) & (US$ Million)
Table 29. Global Microbiome Therapeutics Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 30. Global Microbiome Therapeutics Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 31. Global Microbiome Therapeutics Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 33. Global Microbiome Therapeutics Revenue by Application (2025-2030) & (US$ Million)
Table 34. Global Microbiome Therapeutics Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 35. Global Microbiome Therapeutics Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 36. Seres Therapeutics Company Information
Table 37. Seres Therapeutics Business Overview
Table 38. Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 39. Seres Therapeutics Microbiome Therapeutics Product Portfolio
Table 40. Seres Therapeutics Recent Development
Table 41. Assembly Biosciences Company Information
Table 42. Assembly Biosciences Business Overview
Table 43. Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 44. Assembly Biosciences Microbiome Therapeutics Product Portfolio
Table 45. Assembly Biosciences Recent Development
Table 46. Synthetic Biologics Company Information
Table 47. Synthetic Biologics Business Overview
Table 48. Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 49. Synthetic Biologics Microbiome Therapeutics Product Portfolio
Table 50. Synthetic Biologics Recent Development
Table 51. Interxon Company Information
Table 52. Interxon Business Overview
Table 53. Interxon Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 54. Interxon Microbiome Therapeutics Product Portfolio
Table 55. Interxon Recent Development
Table 56. PureTech Company Information
Table 57. PureTech Business Overview
Table 58. PureTech Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 59. PureTech Microbiome Therapeutics Product Portfolio
Table 60. PureTech Recent Development
Table 61. Synlogic Company Information
Table 62. Synlogic Business Overview
Table 63. Synlogic Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 64. Synlogic Microbiome Therapeutics Product Portfolio
Table 65. Synlogic Recent Development
Table 66. Enterome BioScience Company Information
Table 67. Enterome BioScience Business Overview
Table 68. Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 69. Enterome BioScience Microbiome Therapeutics Product Portfolio
Table 70. Enterome BioScience Recent Development
Table 71. 4D Pharma Company Information
Table 72. 4D Pharma Business Overview
Table 73. 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 74. 4D Pharma Microbiome Therapeutics Product Portfolio
Table 75. 4D Pharma Recent Development
Table 76. Second Genome Company Information
Table 77. Second Genome Business Overview
Table 78. Second Genome Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 79. Second Genome Microbiome Therapeutics Product Portfolio
Table 80. Second Genome Recent Development
Table 81. AOBiome Company Information
Table 82. AOBiome Business Overview
Table 83. AOBiome Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 84. AOBiome Microbiome Therapeutics Product Portfolio
Table 85. AOBiome Recent Development
Table 86. C3 Jian Company Information
Table 87. C3 Jian Business Overview
Table 88. C3 Jian Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. C3 Jian Microbiome Therapeutics Product Portfolio
Table 90. C3 Jian Recent Development
Table 91. Rebiotix Company Information
Table 92. Rebiotix Business Overview
Table 93. Rebiotix Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Rebiotix Microbiome Therapeutics Product Portfolio
Table 95. Rebiotix Recent Development
Table 96. MicroBiome Therapeutics LLC Company Information
Table 97. MicroBiome Therapeutics LLC Business Overview
Table 98. MicroBiome Therapeutics LLC Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
Table 100. MicroBiome Therapeutics LLC Recent Development
Table 101. Metabiomics Company Information
Table 102. Metabiomics Business Overview
Table 103. Metabiomics Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Metabiomics Microbiome Therapeutics Product Portfolio
Table 105. Metabiomics Recent Development
Table 106. Ritter Pharmaceuticals Company Information
Table 107. Ritter Pharmaceuticals Business Overview
Table 108. Ritter Pharmaceuticals Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
Table 110. Ritter Pharmaceuticals Recent Development
Table 111. Symberix Company Information
Table 112. Symberix Business Overview
Table 113. Symberix Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Symberix Microbiome Therapeutics Product Portfolio
Table 115. Symberix Recent Development
Table 116. OpenBiome Company Information
Table 117. OpenBiome Business Overview
Table 118. OpenBiome Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. OpenBiome Microbiome Therapeutics Product Portfolio
Table 120. OpenBiome Recent Development
Table 121. Azitra Company Information
Table 122. Azitra Business Overview
Table 123. Azitra Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Azitra Microbiome Therapeutics Product Portfolio
Table 125. Azitra Recent Development
Table 126. Symbiotix Biotherapies Company Information
Table 127. Symbiotix Biotherapies Business Overview
Table 128. Symbiotix Biotherapies Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
Table 130. Symbiotix Biotherapies Recent Development
Table 131. Osel Company Information
Table 132. Osel Business Overview
Table 133. Osel Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Osel Microbiome Therapeutics Product Portfolio
Table 135. Osel Recent Development
Table 136. Metabogen Company Information
Table 137. Metabogen Business Overview
Table 138. Metabogen Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Metabogen Microbiome Therapeutics Product Portfolio
Table 140. Metabogen Recent Development
Table 141. North America Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 142. North America Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 143. North America Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 144. North America Microbiome Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 145. North America Microbiome Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 146. Europe Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 147. Europe Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 148. Europe Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 149. Europe Microbiome Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 150. Europe Microbiome Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 151. China Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 152. China Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 153. Asia Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 154. Asia Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 155. Asia Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 156. Asia Microbiome Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 157. Asia Microbiome Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 158. MEALA Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 159. MEALA Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 160. MEALA Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 161. MEALA Microbiome Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 162. MEALA Microbiome Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 163. Research Programs/Design for This Report
Table 164. Authors List of This Report
Table 165. Secondary Sources
Table 166. Primary Sources
Table 1. Global Microbiome Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Table 1. Upper GIT Major Manufacturers
Table 2. Lower GIT Major Manufacturers
Table 3. Global Microbiome Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Table 4. C. difficile Infection (CDI) Major Manufacturers
Table 5. Inflammatory Bowel Disease (IBD) Major Manufacturers
Table 6. Orphan Drug Major Manufacturers
Table 7. Immuno-oncology Major Manufacturers
Table 8. Others Major Manufacturers
Table 9. Microbiome Therapeutics Industry Trends
Table 10. Microbiome Therapeutics Industry Drivers
Table 11. Microbiome Therapeutics Industry Opportunities and Challenges
Table 12. Microbiome Therapeutics Industry Restraints
Table 13. Global Microbiome Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
Table 14. Global Microbiome Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 15. Global Microbiome Therapeutics Market Share by Region (2019-2024)
Table 16. Global Microbiome Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 17. Global Microbiome Therapeutics Market Share by Region (2025-2030)
Table 18. Global Microbiome Therapeutics Revenue by Players (US$ Million) & (2019-2024)
Table 19. Global Microbiome Therapeutics Revenue Market Share by Players (2019-2024)
Table 20. Global Microbiome Therapeutics Key Players Ranking, 2022 VS 2023 VS 2024
Table 21. Global Microbiome Therapeutics Key Players Headquarters & Area Served
Table 22. Global Microbiome Therapeutics Players, Product Type & Application
Table 23. Global Microbiome Therapeutics Players Commercialization Time
Table 24. Global Players Market Concentration Ratio (CR5 and HHI)
Table 25. Global Microbiome Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2023)
Table 26. Global Microbiome Therapeutics Revenue by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 27. Global Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 28. Global Microbiome Therapeutics Revenue by Type (2025-2030) & (US$ Million)
Table 29. Global Microbiome Therapeutics Revenue Market Share by Type (2019-2024) & (US$ Million)
Table 30. Global Microbiome Therapeutics Revenue Market Share by Type (2025-2030) & (US$ Million)
Table 31. Global Microbiome Therapeutics Revenue by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 32. Global Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 33. Global Microbiome Therapeutics Revenue by Application (2025-2030) & (US$ Million)
Table 34. Global Microbiome Therapeutics Revenue Market Share by Application (2019-2024) & (US$ Million)
Table 35. Global Microbiome Therapeutics Revenue Market Share by Application (2025-2030) & (US$ Million)
Table 36. Seres Therapeutics Company Information
Table 37. Seres Therapeutics Business Overview
Table 38. Seres Therapeutics Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 39. Seres Therapeutics Microbiome Therapeutics Product Portfolio
Table 40. Seres Therapeutics Recent Development
Table 41. Assembly Biosciences Company Information
Table 42. Assembly Biosciences Business Overview
Table 43. Assembly Biosciences Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 44. Assembly Biosciences Microbiome Therapeutics Product Portfolio
Table 45. Assembly Biosciences Recent Development
Table 46. Synthetic Biologics Company Information
Table 47. Synthetic Biologics Business Overview
Table 48. Synthetic Biologics Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 49. Synthetic Biologics Microbiome Therapeutics Product Portfolio
Table 50. Synthetic Biologics Recent Development
Table 51. Interxon Company Information
Table 52. Interxon Business Overview
Table 53. Interxon Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 54. Interxon Microbiome Therapeutics Product Portfolio
Table 55. Interxon Recent Development
Table 56. PureTech Company Information
Table 57. PureTech Business Overview
Table 58. PureTech Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 59. PureTech Microbiome Therapeutics Product Portfolio
Table 60. PureTech Recent Development
Table 61. Synlogic Company Information
Table 62. Synlogic Business Overview
Table 63. Synlogic Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 64. Synlogic Microbiome Therapeutics Product Portfolio
Table 65. Synlogic Recent Development
Table 66. Enterome BioScience Company Information
Table 67. Enterome BioScience Business Overview
Table 68. Enterome BioScience Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 69. Enterome BioScience Microbiome Therapeutics Product Portfolio
Table 70. Enterome BioScience Recent Development
Table 71. 4D Pharma Company Information
Table 72. 4D Pharma Business Overview
Table 73. 4D Pharma Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 74. 4D Pharma Microbiome Therapeutics Product Portfolio
Table 75. 4D Pharma Recent Development
Table 76. Second Genome Company Information
Table 77. Second Genome Business Overview
Table 78. Second Genome Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 79. Second Genome Microbiome Therapeutics Product Portfolio
Table 80. Second Genome Recent Development
Table 81. AOBiome Company Information
Table 82. AOBiome Business Overview
Table 83. AOBiome Microbiome Therapeutics Revenue and Gross Margin (US$ Million) & (2019-2024)
Table 84. AOBiome Microbiome Therapeutics Product Portfolio
Table 85. AOBiome Recent Development
Table 86. C3 Jian Company Information
Table 87. C3 Jian Business Overview
Table 88. C3 Jian Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 89. C3 Jian Microbiome Therapeutics Product Portfolio
Table 90. C3 Jian Recent Development
Table 91. Rebiotix Company Information
Table 92. Rebiotix Business Overview
Table 93. Rebiotix Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 94. Rebiotix Microbiome Therapeutics Product Portfolio
Table 95. Rebiotix Recent Development
Table 96. MicroBiome Therapeutics LLC Company Information
Table 97. MicroBiome Therapeutics LLC Business Overview
Table 98. MicroBiome Therapeutics LLC Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 99. MicroBiome Therapeutics LLC Microbiome Therapeutics Product Portfolio
Table 100. MicroBiome Therapeutics LLC Recent Development
Table 101. Metabiomics Company Information
Table 102. Metabiomics Business Overview
Table 103. Metabiomics Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 104. Metabiomics Microbiome Therapeutics Product Portfolio
Table 105. Metabiomics Recent Development
Table 106. Ritter Pharmaceuticals Company Information
Table 107. Ritter Pharmaceuticals Business Overview
Table 108. Ritter Pharmaceuticals Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 109. Ritter Pharmaceuticals Microbiome Therapeutics Product Portfolio
Table 110. Ritter Pharmaceuticals Recent Development
Table 111. Symberix Company Information
Table 112. Symberix Business Overview
Table 113. Symberix Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 114. Symberix Microbiome Therapeutics Product Portfolio
Table 115. Symberix Recent Development
Table 116. OpenBiome Company Information
Table 117. OpenBiome Business Overview
Table 118. OpenBiome Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 119. OpenBiome Microbiome Therapeutics Product Portfolio
Table 120. OpenBiome Recent Development
Table 121. Azitra Company Information
Table 122. Azitra Business Overview
Table 123. Azitra Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 124. Azitra Microbiome Therapeutics Product Portfolio
Table 125. Azitra Recent Development
Table 126. Symbiotix Biotherapies Company Information
Table 127. Symbiotix Biotherapies Business Overview
Table 128. Symbiotix Biotherapies Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 129. Symbiotix Biotherapies Microbiome Therapeutics Product Portfolio
Table 130. Symbiotix Biotherapies Recent Development
Table 131. Osel Company Information
Table 132. Osel Business Overview
Table 133. Osel Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 134. Osel Microbiome Therapeutics Product Portfolio
Table 135. Osel Recent Development
Table 136. Metabogen Company Information
Table 137. Metabogen Business Overview
Table 138. Metabogen Microbiome Therapeutics Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 139. Metabogen Microbiome Therapeutics Product Portfolio
Table 140. Metabogen Recent Development
Table 141. North America Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 142. North America Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 143. North America Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 144. North America Microbiome Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 145. North America Microbiome Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 146. Europe Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 147. Europe Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 148. Europe Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 149. Europe Microbiome Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 150. Europe Microbiome Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 151. China Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 152. China Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 153. Asia Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 154. Asia Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 155. Asia Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 156. Asia Microbiome Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 157. Asia Microbiome Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 158. MEALA Microbiome Therapeutics Revenue by Type (2019-2024) & (US$ Million)
Table 159. MEALA Microbiome Therapeutics Revenue by Application (2019-2024) & (US$ Million)
Table 160. MEALA Microbiome Therapeutics Revenue by Country (2019 VS 2023 VS 2030) & (US$ Million)
Table 161. MEALA Microbiome Therapeutics Revenue by Country (2019-2024) & (US$ Million)
Table 162. MEALA Microbiome Therapeutics Revenue by Country (2025-2030) & (US$ Million)
Table 163. Research Programs/Design for This Report
Table 164. Authors List of This Report
Table 165. Secondary Sources
Table 166. Primary Sources
LIST OF FIGURES
Figure 1. Microbiome Therapeutics Product Picture
Figure 2. Global Microbiome Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Microbiome Therapeutics Market Size Share 2019 VS 2023 VS 2030
Figure 4. Upper GIT Picture
Figure 5. Lower GIT Picture
Figure 6. Global Microbiome Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 7. Global Microbiome Therapeutics Market Size Share 2019 VS 2023 VS 2030
Figure 8. C. difficile Infection (CDI) Picture
Figure 9. Inflammatory Bowel Disease (IBD) Picture
Figure 10. Orphan Drug Picture
Figure 11. Immuno-oncology Picture
Figure 12. Others Picture
Figure 13. Global Microbiome Therapeutics Market Size (US$ Million) & (2019-2030)
Figure 14. Global Microbiome Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Microbiome Therapeutics Market Share by Region: 2019 VS 2023 VS 2030
Figure 16. Global Microbiome Therapeutics Players Revenue Share Top 10 and Top 5 in 2023
Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 18. Global Microbiome Therapeutics Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Microbiome Therapeutics Revenue Market Share 2019 VS 2023 VS 2030
Figure 20. Global Microbiome Therapeutics Revenue Market Share by Type (2019-2030)
Figure 21. Global Microbiome Therapeutics Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Microbiome Therapeutics Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 23. Global Microbiome Therapeutics Revenue Market Share by Application (2019-2030)
Figure 24. North America Microbiome Therapeutics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Microbiome Therapeutics Revenue by Type (2025-2030) & (US$ Million)
Figure 26. North America Microbiome Therapeutics Revenue Share by Type (2019-2030)
Figure 27. North America Microbiome Therapeutics Revenue by Application (2025-2030) & (US$ Million)
Figure 28. North America Microbiome Therapeutics Revenue Share by Application (2019-2030)
Figure 29. North America Microbiome Therapeutics Revenue Share by Country (2019-2030)
Figure 30. United States Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Canada Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 32. Europe Microbiome Therapeutics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 33. Europe Microbiome Therapeutics Revenue by Type (2025-2030) & (US$ Million)
Figure 34. Europe Microbiome Therapeutics Revenue Share by Type (2019-2030)
Figure 35. Europe Microbiome Therapeutics Revenue by Application (2025-2030) & (US$ Million)
Figure 36. Europe Microbiome Therapeutics Revenue Share by Application (2019-2030)
Figure 37. Europe Microbiome Therapeutics Revenue Share by Country (2019-2030)
Figure 38. Germany Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. France Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. U.K. Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Italy Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Russia Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Nordic Countries Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. China Microbiome Therapeutics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 45. China Microbiome Therapeutics Revenue by Type (2025-2030) & (US$ Million)
Figure 46. China Microbiome Therapeutics Revenue Share by Type (2019-2030)
Figure 47. China Microbiome Therapeutics Revenue by Application (2025-2030) & (US$ Million)
Figure 48. China Microbiome Therapeutics Revenue Share by Application (2019-2030)
Figure 49. Asia Microbiome Therapeutics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 50. Asia Microbiome Therapeutics Revenue by Type (2025-2030) & (US$ Million)
Figure 51. Asia Microbiome Therapeutics Revenue Share by Type (2019-2030)
Figure 52. Asia Microbiome Therapeutics Revenue by Application (2025-2030) & (US$ Million)
Figure 53. Asia Microbiome Therapeutics Revenue Share by Application (2019-2030)
Figure 54. Asia Microbiome Therapeutics Revenue Share by Country (2019-2030)
Figure 55. Japan Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. South Korea Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. India Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. Australia Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. China Taiwan Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Southeast Asia Microbiome Therapeutics Revenue YoY
Figure 1. Microbiome Therapeutics Product Picture
Figure 2. Global Microbiome Therapeutics Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Microbiome Therapeutics Market Size Share 2019 VS 2023 VS 2030
Figure 4. Upper GIT Picture
Figure 5. Lower GIT Picture
Figure 6. Global Microbiome Therapeutics Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
Figure 7. Global Microbiome Therapeutics Market Size Share 2019 VS 2023 VS 2030
Figure 8. C. difficile Infection (CDI) Picture
Figure 9. Inflammatory Bowel Disease (IBD) Picture
Figure 10. Orphan Drug Picture
Figure 11. Immuno-oncology Picture
Figure 12. Others Picture
Figure 13. Global Microbiome Therapeutics Market Size (US$ Million) & (2019-2030)
Figure 14. Global Microbiome Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Microbiome Therapeutics Market Share by Region: 2019 VS 2023 VS 2030
Figure 16. Global Microbiome Therapeutics Players Revenue Share Top 10 and Top 5 in 2023
Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 18. Global Microbiome Therapeutics Revenue by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 19. Global Microbiome Therapeutics Revenue Market Share 2019 VS 2023 VS 2030
Figure 20. Global Microbiome Therapeutics Revenue Market Share by Type (2019-2030)
Figure 21. Global Microbiome Therapeutics Revenue by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 22. Global Microbiome Therapeutics Revenue Market Share by Application (2019 VS 2023 VS 2030)
Figure 23. Global Microbiome Therapeutics Revenue Market Share by Application (2019-2030)
Figure 24. North America Microbiome Therapeutics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Microbiome Therapeutics Revenue by Type (2025-2030) & (US$ Million)
Figure 26. North America Microbiome Therapeutics Revenue Share by Type (2019-2030)
Figure 27. North America Microbiome Therapeutics Revenue by Application (2025-2030) & (US$ Million)
Figure 28. North America Microbiome Therapeutics Revenue Share by Application (2019-2030)
Figure 29. North America Microbiome Therapeutics Revenue Share by Country (2019-2030)
Figure 30. United States Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 31. Canada Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 32. Europe Microbiome Therapeutics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 33. Europe Microbiome Therapeutics Revenue by Type (2025-2030) & (US$ Million)
Figure 34. Europe Microbiome Therapeutics Revenue Share by Type (2019-2030)
Figure 35. Europe Microbiome Therapeutics Revenue by Application (2025-2030) & (US$ Million)
Figure 36. Europe Microbiome Therapeutics Revenue Share by Application (2019-2030)
Figure 37. Europe Microbiome Therapeutics Revenue Share by Country (2019-2030)
Figure 38. Germany Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 39. France Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 40. U.K. Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 41. Italy Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 42. Russia Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 43. Nordic Countries Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 44. China Microbiome Therapeutics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 45. China Microbiome Therapeutics Revenue by Type (2025-2030) & (US$ Million)
Figure 46. China Microbiome Therapeutics Revenue Share by Type (2019-2030)
Figure 47. China Microbiome Therapeutics Revenue by Application (2025-2030) & (US$ Million)
Figure 48. China Microbiome Therapeutics Revenue Share by Application (2019-2030)
Figure 49. Asia Microbiome Therapeutics Revenue YoY Growth (2019-2030) & (US$ Million)
Figure 50. Asia Microbiome Therapeutics Revenue by Type (2025-2030) & (US$ Million)
Figure 51. Asia Microbiome Therapeutics Revenue Share by Type (2019-2030)
Figure 52. Asia Microbiome Therapeutics Revenue by Application (2025-2030) & (US$ Million)
Figure 53. Asia Microbiome Therapeutics Revenue Share by Application (2019-2030)
Figure 54. Asia Microbiome Therapeutics Revenue Share by Country (2019-2030)
Figure 55. Japan Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 56. South Korea Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 57. India Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 58. Australia Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 59. China Taiwan Microbiome Therapeutics Revenue YoY Growth (US$ Million) & (2019-2030)
Figure 60. Southeast Asia Microbiome Therapeutics Revenue YoY
